GlassScriptPhysician profile
Andy Ionut Iriza
NPI 1588042725
$3,457.24
in general payments reported to CMS, 2019-2025
24 companies · $2,203 in 2025
The $2,203 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.38 · 2022: $116 · 2023: $601 · 2024: $516 · 2025: $2,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,411 · Travel and Lodging: $851 · Education: $57.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,411.37 |
| Travel and Lodging | $850.98 |
| Education | $57.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noah Medical Corporation | $1,047.10 | 2025 | Galaxy |
| Glaxosmithkline, LLC. | $483.62 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $350.22 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $332.79 | 2023-2025 | Fasenra, Tezspire, Airsupra |
| Galvanize Therapeutics, INC | $180.21 | 2025 | Aliya System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.03 | 2023-2024 | Ofev |
| Insmed, INC. | $115.68 | 2024-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $94.98 | 2023-2024 | Dupixent |
| Philips North America LLC | $92.13 | 2022-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Ani Pharmaceuticals, INC. | $88.08 | 2024 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $71.02 | 2024-2025 | Opsumit, Uptravi |
| Amgen INC. | $69.91 | 2023-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $57.48 | 2025 | |
| Merck Sharp & Dohme LLC | $46.66 | 2024-2025 | Winrevair, Zerbaxa, Dificid |
| Novartis Pharmaceuticals Corporation | $45.63 | 2023-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $44.56 | 2023 | Monarch Platform |
| Verona Pharma, INC. | $39.20 | 2025 | Ohtuvayre |
| Baxter Healthcare | $29.44 | 2022 | |
| Genentech USA, INC. | $26.17 | 2023 | Xolair |
| Viatris Specialty LLC | $23.76 | 2025 | Yupelri |
| Zoll Circulation INC | $21.38 | 2020 | |
| Axsome Therapeutics, INC. | $20.90 | 2025 | Sunosi |
| Mylan Specialty L.P. | $19.74 | 2023 | Yupelri |
| La Jolla Pharmaceutical Company | $18.55 | 2025 | Giapreza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Iriza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.